Bullish Case: MDT has rebounded 13.4% in 90 days and remains mean-reverting, while call volume exceeds puts by 70% and Helium’s bullish risk is 30% greater than bearish risk. The return surface favors modest positive outcomes, and AI-assisted surgery plus expanded CE approval offer plausible catalysts. A move through $95 could expose $98–$105, though evidence supports a measured rather than explosive rally.

Bearish Case: Helium’s -1.72% forecast, backwardated term structure, and unusually elevated near-dated uncertainty argue for renewed volatility after the rebound. Market IV is 47.2% for September 5 versus Helium’s 22.8%, while September 4 options show 40–92% IV and costly downside protection. The apparent data conflict, low option-volume percentile, macro risk from SPY’s downside-volatility surface, and mean reversion leave $85–$90 vulnerable.

Potential Outcomes:

1. 45% Range $88–$97: mean reversion and low conviction dominate.
2. 25% Upside $98–$106: catalyst or favorable guidance/clinical read-through; $95 breakout is falsifiable trigger.
3. 20% Downside $82–$88: volatility normalizes lower but spot retraces.
4. 10% Sub-$82: macro, regulatory, recall, or margin shock.

Oracle: neutral-to-mild bearish; defined-risk, hedged structures fit better than naked volatility. Prior downside-tail estimates have not materialized, so they are reduced.

September 02, 2026